Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity. / Christensen, Pernille Kristine Fisker; Hansen, Axel Kornerup; Skov, Søren; Martel, Britta Cathrina; Larsen, Jesper; Høyer-Hansen, Maria Helena; Koch, Janne.
In: PLoS ONE, Vol. 18, e0281005, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity
AU - Christensen, Pernille Kristine Fisker
AU - Hansen, Axel Kornerup
AU - Skov, Søren
AU - Martel, Britta Cathrina
AU - Larsen, Jesper
AU - Høyer-Hansen, Maria Helena
AU - Koch, Janne
N1 - Publisher Copyright: Copyright: © 2023 Christensen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023
Y1 - 2023
N2 - Human immune system (HIS) mouse models can be valuable when cross-reactivity of drug candidates to mouse systems is missing. However, no HIS mouse models of psoriasis have been established. In this study, it was investigated if imiquimod (IMQ) induced psoriasis-like skin inflammation was driven by human immune cells in human FMS-related tyrosine kinase 3 ligand (hFlt3L) boosted (BRGSF-HIS mice). BRGSF-HIS mice were boosted with hFlt3L prior to two or three topical applications of IMQ. Despite clinical skin inflammation, increased epidermal thickness and influx of human immune cells, a human derived response was not pronounced in IMQ treated mice. However, the number of murine neutrophils and murine cytokines and chemokines were increased in the skin and systemically after IMQ application. In conclusion, IMQ did induce skin inflammation in hFlt3L boosted BRGSF-HIS mice, although, a limited human immune response suggest that the main driving cellular mechanisms were of murine origin.
AB - Human immune system (HIS) mouse models can be valuable when cross-reactivity of drug candidates to mouse systems is missing. However, no HIS mouse models of psoriasis have been established. In this study, it was investigated if imiquimod (IMQ) induced psoriasis-like skin inflammation was driven by human immune cells in human FMS-related tyrosine kinase 3 ligand (hFlt3L) boosted (BRGSF-HIS mice). BRGSF-HIS mice were boosted with hFlt3L prior to two or three topical applications of IMQ. Despite clinical skin inflammation, increased epidermal thickness and influx of human immune cells, a human derived response was not pronounced in IMQ treated mice. However, the number of murine neutrophils and murine cytokines and chemokines were increased in the skin and systemically after IMQ application. In conclusion, IMQ did induce skin inflammation in hFlt3L boosted BRGSF-HIS mice, although, a limited human immune response suggest that the main driving cellular mechanisms were of murine origin.
U2 - 10.1371/journal.pone.0281005
DO - 10.1371/journal.pone.0281005
M3 - Journal article
C2 - 36800344
AN - SCOPUS:85148297732
VL - 18
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
M1 - e0281005
ER -
ID: 337601258